Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
Unusual Whales
The RESTORE-FA trial is advancing with modifications following promising results after four weeks of dosing. The forthcoming data, based on 12 weeks of dosing, is anticipated to be unveiled in the first quarter of 2027.
